Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) is co-investing in Warp Drive Bio, an innovative start-up biotechnology company, along with 2 venture capital firms, Third Rock Ventures (TRV), a venture capital firm based in Boston, Massachusetts, and Greylock Partners, a venture capital firm based in Menlo Park, California. Warp Drive Bio is an innovative biotechnology company, focusing on proprietary genomic technology to discover drugs of natural origin.

Warp Drive Bio proprietary technology was conceived by world leading scientist Gregory Verdine, Ph.D., and incubated at Third Rock Ventures for two years. Joining Dr. Verdine as co-founders are George Church, Ph.D. and Jim Wells, Ph.D. The Warp Drive Bio team has been assembling an array of technologies to create a platform for identifying potential drug candidates using microbiology, next generation sequencing, cutting-edge bioinformatics and chemo-informatics. Warp Drive Bio's integrated process pairs a 'genomic search engine' and customized search queries that enable natural products that are hidden within micro-organisms to be identified on the basis of their distinctive genomic signature.

Under the terms of the agreement, Sanofi and TRV / Greylock will invest in Warp Drive Bio at parity. Total program funding over the first 5 years could amount to up to $125 million, including an equity investment of up to $75 million.

Sanofi will give Warp Drive Bio access to its strains library and natural product expertise and will be granted certain access rights to Warp Drive Bio's technology and products, on a worldwide basis.

Warp Drive Bio remains an independent company and retains strategic direction, operational management and the right to develop and commercialize assets. This agreement enables Warp Drive Bio to advance its core research and development plan to proof of concept in collaboration with Sanofi, while also maintaining the ability to secure additional partnerships.

"We are very excited about this investment and collaborative partnership in a start-up biotechnology company based on outstanding science" declared Elias Zerhouni, President, Global Research & Development, Sanofi. "By combining Warp Drive Bio's unique proprietary technology and Sanofi's extensive drug development capabilities, we are convinced that this open and creative model of pharma-biotech partnership will boost innovation for the benefit of patients."

"This innovative collaboration between Sanofi and Third Rock Ventures provides the opportunity to build significant value and the potential for venture capital levels of return," said Alexis Borisy, partner at Third Rock Ventures and interim Chief Executive Officer of Warp Drive Bio. "Importantly, it also enables us to advance and accelerate the development of our proprietary genomics platform, unlock 'nature's drugs' and, ultimately, create breakthrough therapies for patients."

"Revolutionary advances in microbial genomics have provided the blueprints for nature's factories that assemble natural products, and have revealed vast treasure troves of novel natural product drugs hidden within microbes," said Gregory L. Verdine, Ph.D., Harvard University chemical biologist, venture partner at Third Rock Ventures and co-founder of Warp Drive Bio. "Prior to Warp Drive Bio, no one had created a comprehensive discovery engine that selectively mines from nature those products with transformative pharmaceutical potential. Warp Drive Bio has developed that capability and is using it to discover powerful next-generation drugs that target the central circuitry of human cells in completely new ways. We are thrilled to be working closely with Sanofi and our other partners as we aggressively move forward to bring these desperately needed medications to patients suffering from life-threatening and debilitating diseases."

About Warp Drive Bio
Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world's most powerful medicinal chemist, Warp Drive is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within micro-organisms. Key to the Warp Drive approach is the company's proprietary 'genomic search engine' and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signature.

About Third Rock Ventures
Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $800 million and two funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients. The firm has assembled a team with deep expertise and a proven track record of building respected and successful life sciences companies. With decades of complementary, cross-functional operational and leadership experience, the Third Rock team actively engages with its portfolio companies to provide hands-on strategy and experience to successfully launch companies with the best vision, science, operations, people and culture. With offices in Boston, MA and San Francisco, CA, Third Rock is well positioned geographically to closely collaborate with its portfolio companies to achieve their goals.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...